Glipizide
- Generic Name
- Glipizide
- Brand Names
- Glucotrol
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27N5O4S
- CAS Number
- 29094-61-9
- Unique Ingredient Identifier
- X7WDT95N5C
- Background
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea ...
- Indication
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06168812
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT02608177
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Effect of Exenatide on Liver and Heart Fat and Inflammation
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT01951651
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
- Conditions
- Interventions
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 1033
- Registration Number
- NCT01762046
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Joslin Diabetes Center, Boston, Massachusetts, United States
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2013-01-01
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 160
- Registration Number
- NCT01758471
- Locations
- 🇨🇳
Shanghai Clinic Center for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Institute for Endocrine and Metabolic Diseases, Shanghai, Shanghai, China
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
- Conditions
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 213
- Registration Number
- NCT01698775
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT01082796
- Locations
- 🇨🇳
Departmant of Clinical Pharmacology, the First Affiliated Hospital of Lanzhou University, Lanzhou, Gansu, China
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2012-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 530
- Registration Number
- NCT01020123
- Locations
- 🇬🇧
Research Site, West Lothian, United Kingdom
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT00885352
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2639
- Registration Number
- NCT00856284
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.